Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

4050 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-01-01

Study Completion Date

2031-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Management of Symptomatic Advanced Pancreatic Adenocarcinoma

NCT02979483

Pancreas Management Supportive Care Program

ACTIVE_NOT_RECRUITING NA

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)

NCT05475366

Carcinoma, Pancreatic Ductal Prognosis

RECRUITING NA

Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors

NCT01692873

Pancreatic Tumor

COMPLETED NA

INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

NCT04436679

Pancreas Cancer Pancreatic Adenocarcinoma

COMPLETED

Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

NCT02818907

Pancreatic Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The modest efficacy of current therapies for pancreatic cancer calls for the development of prognostic factors to guide patient selection and clinical decision-making based on tumor aggressiveness and risk of death.

The aim of this study is to identify prognostic and predictive factors of response to treatments administered in pancreatic adenocarcinoma, based on a multicenter cohort established on a population derived from current clinical practice. By accurately stratifying patients according to their estimated survival, prognostic tools could aid therapeutic decisions and optimize patient selection in future clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with histologically confirmed pancreatic adenocarcinoma.
* Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
* Diagnosis between January 1, 2003, and December 31, 2030.
* First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
* Age ≥ 18 years.
* Written informed consent

Exclusion Criteria

* Patient under guardianship, curatorship, or judicial protection.
* Pregnant or breastfeeding women.
* Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
* Refusal to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No